8-K current report · filed Aug 25, 2026

Parabilis Medicines Inc (PBLS) 8-K Current Report: August 25, 2026

Item 7.01Item 5.02PBLS overview

Short answer

Parabilis Medicines Inc (PBLS) filed an 8-K current report with the SEC on August 25, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 5.02 (Departure/Election of Directors or Officers). Board expanded to nine directors, adding Craig Tendler as an independent Class II director through the 2028 annual meeting.

Parabilis Medicines Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Board expanded to nine directors, adding Craig Tendler as an independent Class II director through the 2028 annual meeting
  • Tendler joins the Science & Technology Committee, strengthening board-level scientific oversight
  • Equity award: option for 20,294 shares at $39.36 exercise price, vesting monthly over three years
  • Annual compensation: $40,000 Board retainer plus $7,500 Science & Technology Committee retainer
  • No disclosed related-party transactions or selection arrangements, reducing governance conflict concerns

Item 7.01 · Regulation FD Disclosure

  • Tendler appointed to Parabilis Medicines’ Board, adding a new director to the company’s governance structure
  • Appointment announcement dated August 25, 2026, with investor relevance dependent on Tendler’s background and board role

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Parabilis Medicines Inc 8-K filings

Get the next PBLS 8-K as it lands

Follow PBLS for push alerts, or ask the research agent what this filing means.